MiNK Therapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $8,422,853 for the nine months ended that date, along with its first pre-commercial product revenue of $200,000.

Key Highlights

  • Net loss of $8,422,853 for the nine months ended September 30, 2026, compared to a net loss of $9,892,157 for the same period in 2025, according to the filing.
  • First pre-commercial product revenue of $200,000 was recorded in the three and nine months ended September 30, 2026; no such revenue was reported in the comparable 2025 periods.
  • Cash and cash equivalents of $7,470,862 as of September 30, 2026, down from $13,360,340 at December 31, 2025.
  • Accumulated deficit of $165,098,847 as of September 30, 2026, up from $156,675,995 at December 31, 2025.
  • Total stockholders' deficit of $(16,251,418) as of September 30, 2026, compared to $(14,227,659) at December 31, 2025.
  • 5,133,645 shares of common stock outstanding as of November 9, 2026, per the filing's cover page.
  • Related party note of $5,179,444 carried at December 31, 2025 was reduced to zero by September 30, 2026, per the balance sheet.

MiNK Therapeutics Financial Results: Third Quarter and Nine Months Ended September 30, 2026

According to the Form 10-Q filed with the SEC, MiNK Therapeutics, Inc. (NASDAQ:INKT) reported a net loss of $2,552,283 for the three months ended September 30, 2026, compared to a net loss of $2,887,709 for the three months ended September 30, 2025. For the nine-month period, the net loss was $8,422,853 versus $9,892,157 in the prior-year period. Basic and diluted net loss per common share was $(0.50) for the quarter and $(1.69) for the nine months ended September 30, 2026, based on weighted average shares outstanding of 5,102,659 and 4,975,764, respectively.

The filing disclosed that the company recorded $200,000 in pre-commercial product revenue during both the three and nine months ended September 30, 2026, with no comparable revenue in the 2025 periods. Research and development expenses for the nine months were $4,895,275, up from $4,244,255 in the same period of 2025. General and administrative expenses for the nine months were $4,040,669, compared to $4,966,490 in the prior-year period. Operating loss for the nine months ended September 30, 2026 was $8,735,944, versus $9,936,677 in the nine months ended September 30, 2025.

The company's balance sheet as of September 30, 2026 showed total assets of $8,243,058 and total current liabilities of $8,175,239, with due-to-related-parties obligations of $16,319,237. Cash and cash equivalents declined to $7,470,862 from $13,360,340 at year-end 2025. During the nine months ended September 30, 2026, the company raised capital through shares sold at the market, including 193,060 shares for proceeds of $3,019,528 in the first quarter and 120,418 shares for proceeds of $1,366,154 in the second quarter, as reflected in the statements of stockholders' deficit. The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.

What Was Disclosed

MiNK Therapeutics filed its Form 10-Q for the quarter ended September 30, 2026, reporting a nine-month net loss of $8,422,853, its first pre-commercial product revenue, declining cash balances, and a growing accumulated deficit of $165,098,847.